Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Suzanne R Hayman

Showing results (41-50 of 242) with videos related to

Pageof 25
Sort By:
Haematologica|May 6, 2017
Serial measurements of circulating plasma cells before and after induction therapy have an independent prognostic impact in patients with multiple myeloma undergoing upfront autologous transplantationRajshekhar Chakraborty, Eli Muchtar, Shaji K Kumar, et al.
American Journal of Hematology|February 18, 2011
Changes in serum-free light chain rather than intact monoclonal immunoglobulin levels predicts outcome following therapy in primary amyloidosisShaji K Kumar, Angela Dispenzieri, Martha Q Lacy, et al.
Blood Coagulation & Fibrinolysis : an International Journal in Haemostasis and Thrombosis|July 29, 2015
Autologous stem cell transplantation in immunoglobulin light chain amyloidosis with factor X deficiencyStefan Cordes, Morie A Gertz, Francis K Buadi, et al.
American Journal of Hematology|October 1, 2011
Hematopoietic recovery kinetics predicts for poor CD34+ cell mobilization after cyclophosphamide chemotherapy in multiple myelomaGuner Hayri Ozsan, Ivana N Micallef, Angela Dispenzieri, et al.
Amyloid : the International Journal of Experimental and Clinical Investigation : the Official Journal of the International Society of Amyloidosis|March 14, 2018
Digoxin use in systemic light-chain (AL) amyloidosis: contra-indicated or cautious use?Eli Muchtar, Morie A Gertz, Shaji K Kumar, et al.
Blood|July 19, 2013
Implications of continued response after autologous stem cell transplantation for multiple myelomaWilson I Gonsalves, Morie A Gertz, Angela Dispenzieri, et al.
Haematologica|June 5, 2013
A detailed evaluation of the current renal response criteria in AL amyloidosis: is it time for a revision?Nelson Leung, Siobhan V Glavey, Shaji Kumar, et al.
Bone Marrow Transplantation|June 14, 2019
The impact of re-induction prior to salvage autologous stem cell transplantation in multiple myelomaKevin C Miller, Morie A Gertz, Francis K Buadi, et al.
Bone Marrow Transplantation|August 18, 2018
Comparable outcomes using propylene glycol-free melphalan for autologous stem cell transplantation in multiple myelomaKevin C Miller, Morie A Gertz, Francis K Buadi, et al.
Mayo Clinic Proceedings|January 17, 2003
Response rate, durability of response, and survival after thalidomide therapy for relapsed multiple myelomaShaji Kumar, Morie A Gertz, Angela Dispenzieri, et al.
Pageof 25

Showing results (41-50 of 242) with videos related to

Sort By:
Pageof 25
Haematologica|May 6, 2017
Serial measurements of circulating plasma cells before and after induction therapy have an independent prognostic impact in patients with multiple myeloma undergoing upfront autologous transplantationRajshekhar Chakraborty, Eli Muchtar, Shaji K Kumar, et al.
American Journal of Hematology|February 18, 2011
Changes in serum-free light chain rather than intact monoclonal immunoglobulin levels predicts outcome following therapy in primary amyloidosisShaji K Kumar, Angela Dispenzieri, Martha Q Lacy, et al.
Blood Coagulation & Fibrinolysis : an International Journal in Haemostasis and Thrombosis|July 29, 2015
Autologous stem cell transplantation in immunoglobulin light chain amyloidosis with factor X deficiencyStefan Cordes, Morie A Gertz, Francis K Buadi, et al.
American Journal of Hematology|October 1, 2011
Hematopoietic recovery kinetics predicts for poor CD34+ cell mobilization after cyclophosphamide chemotherapy in multiple myelomaGuner Hayri Ozsan, Ivana N Micallef, Angela Dispenzieri, et al.
Amyloid : the International Journal of Experimental and Clinical Investigation : the Official Journal of the International Society of Amyloidosis|March 14, 2018
Digoxin use in systemic light-chain (AL) amyloidosis: contra-indicated or cautious use?Eli Muchtar, Morie A Gertz, Shaji K Kumar, et al.
Blood|July 19, 2013
Implications of continued response after autologous stem cell transplantation for multiple myelomaWilson I Gonsalves, Morie A Gertz, Angela Dispenzieri, et al.
Haematologica|June 5, 2013
A detailed evaluation of the current renal response criteria in AL amyloidosis: is it time for a revision?Nelson Leung, Siobhan V Glavey, Shaji Kumar, et al.
Bone Marrow Transplantation|June 14, 2019
The impact of re-induction prior to salvage autologous stem cell transplantation in multiple myelomaKevin C Miller, Morie A Gertz, Francis K Buadi, et al.
Bone Marrow Transplantation|August 18, 2018
Comparable outcomes using propylene glycol-free melphalan for autologous stem cell transplantation in multiple myelomaKevin C Miller, Morie A Gertz, Francis K Buadi, et al.
Mayo Clinic Proceedings|January 17, 2003
Response rate, durability of response, and survival after thalidomide therapy for relapsed multiple myelomaShaji Kumar, Morie A Gertz, Angela Dispenzieri, et al.
Pageof 25